The lifestyle interventions should be monitored, adapted, and perpetuated in an informed consent with the patient over the years, regardless of whether additional medical or surgical therapy is started in the course of T2D or obesity ( Incretin-based therapies Incretins are hormones that are secreted from enteroendocrine cells in the gut mucosa after a meal
However, lifestyle interventions are notoriously difficult to maintain [135], suggesting that some patients may benefit from pharmacological therapy
We combat this with encapsulated delivery (more powerful than liposomal) plus sunflower lecithin to support digestion
Additionally, certain peptides can stimulate osteoblast activity (the cells responsible for building new bone) while also reducing the breakdown of bone tissue
These are not eligibility criteria, but rather areas of particular interest: paediatric rare diseases, rapidly progressive rare diseases, and rare diseases with no approved therapeutic options or substantial residual unmet medical need despite existing treatments
